Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 2/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 3/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2322584 | 0.85 | MCHR1 (0.45) | BACE1MCHR1CYP2D6CHRM1HTR2A | |
| SCHEMBL29471995 | 0.79 | BACE1 (0.40) | GRM5BACE1MCHR1CYP2D6CHRM1 | |
| SCHEMBL22531721 | 0.79 | BACE1 (0.40) | GRM5BACE1MCHR1CYP2D6CHRM1 | |
| SCHEMBL3958689 | 0.78 | CCR1 (0.43) | ADRA2AADRA2BADRA2CPLAUGRM5 | |
| SCHEMBL1914210 | 0.78 | GRM5 (0.39) | GRM5 | |
| SCHEMBL3348341 | 0.76 | GRM5 (0.51) | GRM5BACE1 | |
| SCHEMBL19453039 | 0.76 | HCAR2 (0.34) | GRM5 | |
| SCHEMBL3212577 | 0.76 | ADRA2A (0.36) | ADRA2AADRA2BADRA2CPLAUGRM5 | |
| SCHEMBL29350657 | 0.76 | ADRA2A (0.37) | ADRA2AADRA2BADRA2CGRM5BACE1 | |
| SCHEMBL1137069 | 0.76 | ADRA2A (0.37) | ADRA2AADRA2BADRA2CGRM5BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116217558-A | GLP-1 receptor agonist, preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2023-06-06 | — | — | CN | disclosed |
| US-20230058961-A1 | SUBSTITUTED HETEROCYCLICS WITH THERAPEUTIC ACTIVITY IN HIV | NATIONAL INSTITUTES OF HEALTH | 2023-02-23 | — | — | US | disclosed |
| CN-112566636-A | Compound and use thereof | 优曼尼蒂治疗公司 | 2021-03-26 | — | — | CN | disclosed |
| EP-3784234-A1 | COMPOUNDS AND USES THEREOF | Yumanity Therapeutics, Inc. (US) | 2021-03-03 | — | — | EP | disclosed |
| US-10919885-B2 | Compounds and uses thereof | YUMANITY THERAPEUTICS, INC. (US) | 2021-02-16 | — | — | US | disclosed |
| US-10919885-B2 | Compounds and uses thereof | YUMANITY THERAPEUTICS, INC. (US) | 2021-02-16 | — | — | US | disclosed |
| US-20190330198-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-31 | — | — | US | disclosed |
| US-20190330198-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-31 | — | — | US | disclosed |
| EP-2670738-A2 | 1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-12-11 | — | — | EP | disclosed |
| CN-103339117-A | 1,4 oxazines as bace1 and/or bace2 inhibitors | HOFFMANN LA ROCHE | 2013-10-02 | — | — | CN | disclosed |
| US-8399459-B2 | 1,4 oxazines as BACE1 and/or BACE2 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2013-03-19 | — | — | US | disclosed |
| WO-2012104263-A2 | 1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-09 | — | — | WO | disclosed |
| US-20120196863-A1 | 1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | SIENA BIOTECH S.P.A. (IT) | 2012-08-02 | — | — | US | disclosed |
| US-5534635-A | Process for preparing pyridine-2-carboxamides | HOFFMANN-LA ROCHE INC. (US) | 1996-07-09 | — | — | US | disclosed |
| US-5380861-A | Process for preparing pyridine 2-carboxamides | HOFFMANN-LA ROCHE INC. (US) | 1995-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230058961-A1 | SUBSTITUTED HETEROCYCLICS WITH THERAPEUTIC ACTIVITY IN HIV | CD4, NFATC1, PAICS | ADRA2A 3045/4885ADRA2B 3036/4885ADRA2C 2637/4885 |
| US-20120196863-A1 | 1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | BACE2, BACE1, PSEN1 | ADRA2A 597/4885ADRA2B 640/4885ADRA2C 546/4885 |
| US-10919885-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | ADRA2A 3111/4885ADRA2B 3489/4885ADRA2C 2284/4885 |
| US-20190330198-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | ADRA2A 3111/4885ADRA2B 3489/4885ADRA2C 2284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.